Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Documented evidence of active multiple myeloma:~  * Newly diagnosed, not candidate for transplant~ * Relapsed/refractory who have received up to 3 prior lines of therapy~* Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:~  * Not refractory to prior Lenalidomide which is defined as no progression while receiving Lenalidomide or within 60 days of last dose of Lenalidomide~ * Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event (AE)~Exclusion Criteria:~* Target Disease Exceptions~  * Plasma cell leukemia~ * Monoclonal gammopathy of undetermined significance (MGUS)~ * Smoldering Myeloma~* Primary amyloidosis~* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elotuzumab + Lenalidomide/Dexamethasone (Type: EXPERIMENTAL): Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).